热门资讯> 正文
Vertex再次创下每股收益，第一季度净利润增长56%
2024-05-07 05:21
- Vertex Pharmaceuticals (NASDAQ:VRTX) has continued its string of quarterly EPS beats as net income in Q1 2024, on a non-GAAP basis, surged ~56% compared to the year-ago period.
- Non-GAAP net income in the quarter was ~$1.24B vs. $794M in Q1 2023. Non-GAAP EPS was $4.76 vs. $3.05.
- Revenues in its key cystic fibrosis franchise of Trakafta and Kaftrio rose ~18% year over year to ~$2.5B.
- Top and bottom line results were a beat on both.
- Vertex (VRTX) reiterated prior 2024 product revenue guidance of $10.55B-$10.75B. Consensus revenue guidance is $10.72B.
- The company ended the quarter (March 31) with cash and cash equivalents of ~$14.6B, a ~7% increase from Dec. 31, 2023.
- Vertex shares are trading mostly flat in after-hours trading Monday.
More on Vertex Pharmaceuticals
- Vertex Pharmaceuticals: Alpine Accelerates Aspiration To Become Biotech Powerhouse
- Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement
- What Vertex Pharmaceuticals Is Getting With Acquisition Of Alpine Immune Sciences
- Vertex Pharmaceuticals Non-GAAP EPS of $4.76 beats by $0.70, revenue of $2.69B beats by $110M
- J&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
